Metabolomic predictors of insulin resistance and diabetes. Metabolomic predictors of insulin resistance and diabetes

Our lab has identified and validated novel metabolite profiles of those destined to develop overt T2D. These metabolites were elevated up to 12 years before the onset of T2D in individuals who were initially glucose-tolerant; improved prediction of T2D beyond clinical risk factors and established biochemical markers; and have been validated by other groups. We have now extended our studies to participants in the Jackson Heart Study (JHS), an African American (AA) population with a high prevalence of T2D and its complications. We have also tested the predictive value of metabolites in a key clinical trial, the Diabetes Prevention Program (DPP). Our study has leveraged critical advances. Beyond the named metabolites that we have associated with incident T2D, our recent "whole metabolome"... (for more see dbGaP study page.)

本研究团队已鉴定并验证了将进展为显性2型糖尿病（Type 2 Diabetes, T2D）人群的新型代谢物谱（metabolite profiles）。这些代谢物在初始糖耐量正常（glucose-tolerant）的个体中，可在2型糖尿病发病前长达12年即出现水平升高；相较于临床风险因素与公认生化标志物，该代谢物谱可提升2型糖尿病的预测效能；且该发现已被其他研究团队验证。目前我们已将研究拓展至杰克逊心脏研究（Jackson Heart Study, JHS）的参与者队列，该群体为非洲裔美国人（African American, AA），其2型糖尿病及其并发症的患病率较高。此外，我们还在一项关键临床试验——糖尿病预防项目（Diabetes Prevention Program, DPP）中验证了代谢物的预测价值。本研究依托了多项关键技术进展。除了我们已与新发2型糖尿病相关联的上述代谢物外，我们近期开展的“全代谢组”相关研究……（更多详情请参见dbGaP研究页面）